Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of SPARC1203 in Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients aged 18 to 65 years (both inclusive) with history of seasonal allergic rhinitis and positive skin prick test~Exclusion Criteria:~* History or presence of perennial allergic rhinitis~* Upper or lower respiratory tract infection 2 weeks before Visit 2~* Significant pulmonary disease other than allergic rhinitis or mild asthma controlled by beta-2-agonists alone~* Immunizations or vaccinations within 4 weeks prior to Visit 1

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- SPARC1203 low dose (Type: EXPERIMENTAL): None
- SPARC1203 mid dose (Type: EXPERIMENTAL): None
- SPARC1203 high dose (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).